Provided by Tiger Trade Technology Pte. Ltd.

Galera Therapeutics, Inc.

0.0320
+0.006726.48%
Volume:505.97K
Turnover:14.45K
Market Cap:2.41M
PE:-0.31
High:0.0322
Open:0.0250
Low:0.0250
Close:0.0253
52wk High:0.0451
52wk Low:0.0151
Shares:75.46M
Float Shares:56.72M
Volume Ratio:8.00
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1024
EPS(LYR):-0.3470
ROE:-1063.11%
ROA:-55.36%
PB:-0.02
PE(LYR):-0.09

Loading ...

Company Profile

Company Name:
Galera Therapeutics, Inc.
Exchange:
OTCQB
Establishment Date:
2012
Employees:
3
Office Location:
101 Lindenwood Drive,Suite 225,Malvern,Pennsylvania,United States
Zip Code:
19355
Fax:
- -
Introduction:
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.